Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $160.1 million.

  • Ascendis Pharma A's Non-Current Assets rose 2145.94% to $160.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.1 million, marking a year-over-year increase of 2145.94%. This contributed to the annual value of $128.4 million for FY2024, which is 287.02% down from last year.
  • As of Q3 2025, Ascendis Pharma A's Non-Current Assets stood at $160.1 million, which was up 2145.94% from $152.8 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Non-Current Assets peaked at $1.3 billion during Q4 2021, and registered a low of $126.8 million during Q4 2024.
  • Moreover, its 5-year median value for Non-Current Assets was $160.1 million (2025), whereas its average is $249.0 million.
  • In the last 5 years, Ascendis Pharma A's Non-Current Assets surged by 634055.96% in 2021 and then plummeted by 8672.05% in 2022.
  • Ascendis Pharma A's Non-Current Assets (Quarter) stood at $1.3 billion in 2021, then tumbled by 86.72% to $169.6 million in 2022, then dropped by 22.07% to $132.2 million in 2023, then decreased by 4.1% to $126.8 million in 2024, then rose by 26.31% to $160.1 million in 2025.
  • Its Non-Current Assets stands at $160.1 million for Q3 2025, versus $152.8 million for Q2 2025 and $147.2 million for Q1 2025.